Page last updated: 2024-12-08
dipyrandium
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
dipyrandium: RN given is from CA online & refers to (3beta,17beta)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 160228 |
| MeSH ID | M0046078 |
Synonyms (9)
| Synonym |
|---|
| dipyrandium |
| 1,1'-androstan-3beta,17beta-diylbis(1-methylpyrrolidinium) |
| unii-z4vbl3r6f9 |
| pyrrolidinium, 1,1'-((3beta,5alpha,17beta)-androstane-3,17-diyl)bis(1-methyl- |
| 89121-09-5 |
| pyrrolidinium, 1,1'-((3.beta.,5.alpha.,17.beta.)-androstane-3,17-diyl)bis(1-methyl- |
| 1-((3s,5s,8r,9s,10s,13s,14s,17s)-10,13-dimethyl-3-(1-methylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta(a)phenanthren-17-yl)-1-methylpyrrolidin-1-ium |
| 1,1'-androstan-3.beta.,17.beta.-diylbis(1-methylpyrrolidinium) |
| Z4VBL3R6F9 , |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||